Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8527 PK in Hepatic Impairment
NCT07025551Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mk-8527 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co. Primary endpoints: Area under the concentration versus time curve from 0 to the time of the last quantifiable sample at 168 hours, Area under the concentration versus time curve from 0 to infinity at 168 hours and 5 more. Started Sep 2025; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT07025551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025551.